89bio, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
89bio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q4 2024.
  • 89bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $5.21M, a 28.9% increase year-over-year.
  • 89bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $20.6M, a 28.1% increase year-over-year.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20.6M, a 28.1% increase from 2023.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $16.1M, a 55.5% increase from 2022.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10.4M, a 19.3% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $20.6M $5.21M +$1.17M +28.9% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $19.5M $5.26M +$881K +20.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $18.6M $5.17M +$1.03M +24.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $17.6M $5M +$1.45M +40.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $16.1M $4.04M +$1.28M +46.4% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $14.8M $4.38M +$1.88M +75.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $12.9M $4.14M +$1.55M +60% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $11.4M $3.55M +$1.04M +41.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $10.4M $2.76M +$604K +28% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $9.75M $2.5M +$186K +8.04% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $9.57M $2.59M +$169K +6.99% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $9.4M $2.51M +$719K +40.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $8.68M $2.15M +$904K +72.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-01
Q3 2021 $7.77M $2.31M +$1.16M +101% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $6.61M $2.42M +$1.51M +166% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $5.11M $1.79M +$1.3M +264% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $3.81M $1.25M +$1.08M +653% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $2.72M $1.15M +$1.04M +930% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $1.68M $910K +$834K +1097% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $847K $493K +$458K +1309% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $389K $166K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $112K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $76K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $35K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.